Mulligan Margaret Jean 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Nov 10, 2010
Insider Transaction Report
Form 4
Mulligan Margaret Jean
EVP, CFO
Transactions
- Exercise/Conversion
Common Shares, no par value
2010-11-08+102,658→ 130,658 total - Tax Payment
Common Shares, no par value
2010-11-08$26.12/sh−47,644$1,244,461→ 83,014 total - Exercise/Conversion
Restricted Share Units
2010-11-08−51,329→ 0 totalFrom: 2010-11-08Exp: 2014-08-05→ Common Shares, no par value (51,329 underlying)
Footnotes (3)
- [F1]Each Restricted Share Unit ("RSU") represents a contingent right to receive one common share, no par value, of Valeant Pharmaceuticals International, Inc. and is subject to performance based vesting criteria, providing for vesting ranging from zero (0) to two hundred percent (200%).
- [F2]Represents performance based RSUs that accelerated at 200% in connection with the merger between the issuer (formerly known as Biovail Corporation) and Valeant Pharmaceuticals International and vested following the completion of the issuer's blackout period restrictions on November 8, 2010.
- [F3]Common shares withheld from the issuance of common shares to the Reporting Person to satisfy the tax withholding obligations due upon vesting of RSUs.